A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Inclusion Criteria:

• Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarkeranalysis

• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bonelesion biopsies are not acceptable.

• Eastern Cooperative Oncology Group Performance Status of 0 or 1

• Radiographically documented progressive disease on or after the most recent therapy

• Received standard-of-care therapies, (except for Part 1C, where participants withprior docetaxel use for the advanced/metastatic setting will be excluded), includingan available programmed death (ligand)-1 inhibitor known to be effective in thetumor type for which they are being evaluated

• Advanced or metastatic disease and have received, be refractory to, not be acandidate for, or be intolerant of existing therapies known to provide clinicalbenefit for the condition of the participant

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Primary central nervous system (CNS) malignancy

• Untreated CNS metastases

• Leptomeningeal metastases

• Concurrent malignancy requiring treatment or history of prior malignancy activewithin 2 years prior to the first dose of study treatment

• Active, known, or suspected autoimmune disease

• Condition requiring systemic treatment with either corticosteroids within 14 days orother immunosuppressive medications within 30 days of the first dose of studytreatment

• Prior organ or tissue allograft

• Uncontrolled or significant cardiovascular disease

• Major surgery within 4 weeks of study drug administration

• History of or with active interstitial lung disease or pulmonary fibrosis

Other protocol-defined inclusion/exclusion criteria apply